stoxline Quote Chart Rank Option Currency Glossary
  
Leap Therapeutics, Inc. (LPTX)
2.016  -0.054 (-2.6%)    06-18 10:37
Open: 2.03
High: 2.065
Volume: 33,128
  
Pre. Close: 2.07
Low: 2.01
Market Cap: 77(M)
Technical analysis
2024-06-18 10:20:33 AM
Short term     
Mid term     
Targets 6-month :  3.05 1-year :  3.5
Resists First :  2.61 Second :  3
Pivot price 2.24
Supports First :  1.98 Second :  1.65
MAs MA(5) :  2.11 MA(20) :  2.29
MA(100) :  2.75 MA(250) :  2.56
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  12.6 D(3) :  13.8
RSI RSI(14): 30.2
52-week High :  5 Low :  1.23
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ LPTX ] has closed above bottom band by 5.0%. Bollinger Bands are 42% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.11 - 2.13 2.13 - 2.14
Low: 1.99 - 2 2 - 2.02
Close: 2.04 - 2.07 2.07 - 2.09
Company Description

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Headline News

Fri, 07 Jun 2024
Leap Therapeutics (NASDAQ:LPTX) Trading Down 4.3% - MarketBeat

Mon, 13 May 2024
LPTX Stock Earnings: Leap Therapeutics Beats EPS for Q1 2024 - MSN

Mon, 13 May 2024
Leap Therapeutics Reports First Quarter 2024 Financial Results - PR Newswire

Mon, 13 May 2024
Leap Therapeutics: The DisTinGuish Trial Provides A Near-Term Catalyst - Seeking Alpha

Thu, 11 Apr 2024
Leap Therapeutics secures $40 million in private placement - Investing.com ZA - Investing.com South Africa

Thu, 11 Apr 2024
Leap Therapeutics Announces $40 Million Private Placement - citybiz

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 38 (M)
Shares Float 27 (M)
Held by Insiders 14.1 (%)
Held by Institutions 34.1 (%)
Shares Short 1,350 (K)
Shares Short P.Month 1,450 (K)
Stock Financials
EPS -1.25
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.85
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -44.2 %
Return on Equity (ttm) -74.5 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.52
Qtrly Earnings Growth 0 %
Operating Cash Flow -47 (M)
Levered Free Cash Flow -30 (M)
Stock Valuations
PE Ratio -1.62
PEG Ratio 0.5
Price to Book value 1.09
Price to Sales 0
Price to Cash Flow -1.66
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android